Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Rowland-Yeo

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
CPT: Pharmacometrics & Systems Pharmacology|August 16, 2013
Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and developmentHm Jones, K Rowland-Yeo
Heart (British Cardiac Society)|May 9, 2002
Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used?K Rowland Yeo, W W Yeo
CPT: Pharmacometrics & Systems Pharmacology|July 21, 2016
Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6A Ke, Z Barter, K Rowland-Yeo, et al.
Biopharmaceutics & Drug Disposition|July 5, 2011
Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factorsH K Crewe, Z E Barter, K Rowland Yeo, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 5, 2011
Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnoverK Rowland Yeo, R L Walsky, M Jamei, et al.
Clinical Pharmacology and Therapeutics|April 29, 1998
Protein binding of aspirin and salicylate measured by in vivo ultrafiltrationP Ghahramani, K Rowland-Yeo, W W Yeo, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|June 14, 2006
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variabilityE M Howgate, K Rowland Yeo, N J Proctor, et al.
Clinical Pharmacokinetics|July 25, 2013
A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineM Jamei, F Bajot, S Neuhoff, et al.
Biopharmaceutics & Drug Disposition|November 25, 2010
Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populationsZ E Barter, H F Perrett, K Rowland Yeo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 26, 2004
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamineA Heydari, K Rowland Yeo, M S Lennard, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
CPT: Pharmacometrics & Systems Pharmacology|August 16, 2013
Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and developmentHm Jones, K Rowland-Yeo
Heart (British Cardiac Society)|May 9, 2002
Lipid lowering in patients with diabetes mellitus: what coronary heart disease risk threshold should be used?K Rowland Yeo, W W Yeo
CPT: Pharmacometrics & Systems Pharmacology|July 21, 2016
Towards a Best Practice Approach in PBPK Modeling: Case Example of Developing a Unified Efavirenz Model Accounting for Induction of CYPs 3A4 and 2B6A Ke, Z Barter, K Rowland-Yeo, et al.
Biopharmaceutics & Drug Disposition|July 5, 2011
Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factorsH K Crewe, Z E Barter, K Rowland Yeo, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|May 5, 2011
Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnoverK Rowland Yeo, R L Walsky, M Jamei, et al.
Clinical Pharmacology and Therapeutics|April 29, 1998
Protein binding of aspirin and salicylate measured by in vivo ultrafiltrationP Ghahramani, K Rowland-Yeo, W W Yeo, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|June 14, 2006
Prediction of in vivo drug clearance from in vitro data. I: impact of inter-individual variabilityE M Howgate, K Rowland Yeo, N J Proctor, et al.
Clinical Pharmacokinetics|July 25, 2013
A mechanistic framework for in vitro-in vivo extrapolation of liver membrane transporters: prediction of drug-drug interaction between rosuvastatin and cyclosporineM Jamei, F Bajot, S Neuhoff, et al.
Biopharmaceutics & Drug Disposition|November 25, 2010
Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populationsZ E Barter, H F Perrett, K Rowland Yeo, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 26, 2004
Mechanism-based inactivation of CYP2D6 by methylenedioxymethamphetamineA Heydari, K Rowland Yeo, M S Lennard, et al.
Pageof 2